

Supporting Information for Multiplexed and extraction-free amplification for simplified SARS-CoV-2 RT-PCR tests

Samantha A. Byrnes*[‡], Ryan Gallagher*[‡], Amy Steadman, Crissa Bennett, Rafael Rivera, Corrie Ortega, S. Timothy Motley, Paras Jain, Bernhard H. Weigl, John T. Connelly*
Global Good Fund, Intellectual Ventures, Bellevue, WA, USA

This supporting information includes two figures, four tables, and some additional methods.

Table S1. Primer and probe sequences for each assay. All sequences are from the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel(1). All oligos were ordered with HPLC purification from IDT (Coralville, IA, USA).

N1 RT-PCR	
N1 forward primer	GACCCCAAATCAGCGAAAT
N1 reverse primer	TCTGGTACTGCCAGTTGAATCTG
N1 singleplex probe	FAM-ACCCCGCATTACGTTTGGTGGACC-IBFQ
N1 triplex probe	FAM-ACCCCGCATTACGTTTGGTGGACC-IBFQ
N2 RT-PCR	
N2 forward primer	TTACAAACATTGGCCGCAA
N2 reverse primer	GCGCGACATTCCGAAGAA
N2 singleplex probe	FAM-ACAATTTGCCCCAGCGCTTAG-IBFQ
N2 triplex probe	TEXASRED-ACAATTTGCCCCAGCGCTTAG-IBRQ
RP RTqPCR	
RP forward primer	AGATTTGGACCTGCGAGCG
RP reverse primer	AGATTTGGACCTGCGAGCG
RP singleplex probe	FAM-TTCTGACCTGAAGGCTCTGCGCG-IBFQ
RP triplex probe	Cy5-TTCTGACCTGAAGGCTCTGCGCG-IBRQ

Testing the specificity of the multiplex RT-PCR. We also tested the specificity of the multiplex RT-PCR using 78 clinical samples from Discovery Life Sciences. All samples were SARS-CoV-2 negative and 17 were positive for a variety of other respiratory infections including: influenza A and B, respiratory syncytial virus, pneumoniae, and coronavirus NL63, HKU1, or OC43. None of the samples were positive for SARS-CoV-2 when tested with the multiplex reaction, **Table S2**.

Table S2. Ct values each patient sample received from Discovery Life Sciences to test the specificity of the multiplex SARS-CoV-2 RT-PCR. Any Ct above 40 was considered a negative result to align with MIQE guidelines(4). All samples are considered negative based on the CDC guidelines because there were no cases where both N1 and N2 were detected.

Patient Sample ID	Clinical Test Result	N1 Ct Singleplex	N1 Ct Multiplex	N2 Ct Singleplex	N2 Ct Multiplex	RP Ct Singleplex	RP Ct Multiplex
DLS0085387	Pos – flu B	-	-	-	-	30.22	29.92
DLS0085388	Pos – flu B	-	37.70	-	-	26.11	25.80
DLS0085395	Pos – flu A	-	-	-	-	22.06	21.92
DLS0085406	-	-	-	-	-	26.26	26.03
DLS0085410	-	-	-	-	-	29.55	29.33
DLS0085414	-	-	37.79	-	-	26.79	26.71
DLS0085415	-	-	-	-	-	26.56	26.38

DLS0085418	-	-	-	-	-	31.36	30.80
DLS0085421	Pos – NL63 Coronavirus	-	-	-	-	23.56	23.3
DLS0085425	-	-	-	-	-	27.16	26.89
DLS0085430	-	-	-	-	-	27.43	27.13
DLS0085431	-	-	-	-	-	22.67	22.3
DLS0085435	-	-	-	-	-	28.43	28.37
DLS0085437	-	-	-	-	-	36.32	34.07
DLS0085444	-	-	-	-	-	28.91	28.62
DLS0085452	Pos – RSV	-	-	-	-	23.71	26.03
DLS0085464	Pos – HKU1 Coronavirus	-	-	-	-	29.21	28.90
DLS0085468	Pos – HKU1 Coronavirus	-	-	-	-	20.96	20.83
DLS0085473	Pos – C. pneumoniae	-	-	-	-	26.87	26.74
KH20-04812	Pos – flu A	-	-	-	-	25.45	25.39
DLS0085420	Pos – OC43 Coronavirus	-	-	-	-	25.03	27.40
DLS0085456	Pos – HKU1 Coronavirus	-	-	-	-	28.03	30.60
DLS0085457	Pos – flu A H1	-	-	-	37.87	25.33	27.88
DLS0085459	Pos – NL63 Coronavirus	-	-	-	-	30.28	32.93
DLS0085460	Pos – OC43 Coronavirus	-	-	-	-	26.83	29.15
DLS0085462	Pos – flu A H1	-	-	-	-	23.99	26.54
DLS0085471	Pos – HKU1 Coronavirus	-	-	-	-	26.00	28.61
DLS0085472	Pos – NL63 Coronavirus	-	-	-	-	25.82	28.01
149969	-	-	-	-	-	26.79	29.02
151276	-	-	-	-	-	31.62	33.97
151280	-	-	-	-	-	27.58	30.82
151281	-	-	-	-	-	28.33	31.71
151290	-	-	-	-	-	29.01	31.33
151292	-	-	-	-	-	27.19	29.45
151363	-	-	-	-	-	26.60	28.85
155923	-	-	-	-	-	-	-
155924	-	-	-	-	-	30.93	33.77
155928	-	-	-	-	-	24.93	26.81
155930	-	-	-	-	-	29.12	31.22
155933	-	-	-	-	-	32.65	34.21
155935	-	-	-	-	-	31.53	35.37
155937	-	-	-	-	-	29.67	33.23
155941	-	-	-	-	39.2	28.18	31.21
155942	-	-	-	-	-	33.43	36.18
155943	-	-	-	-	-	31.58	34.34
155944	-	-	-	-	-	29.02	31.81
155947	-	-	-	-	-	24.04	26.50
155949	-	-	-	-	-	26.39	29.11
155953	-	-	-	-	-	27.15	29.31
155958	-	-	-	-	-	26.61	29.18
155959	-	-	-	-	-	27.78	30.25

155960	-	-	-	-	-	30.15	32.72
155961	-	-	-	-	-	27.77	30.27
155966	-	-	-	-	-	23.93	26.27
155967	-	-	-	-	-	29.44	31.88
155968	-	-	-	-	-	-	-
155971	-	-	-	-	-	33.37	35.48
155976	-	-	-	-	-	28.38	30.95
155977	-	-	-	-	-	29.84	31.96
155978	-	-	-	-	-	31.25	33.44
155980	-	-	-	-	-	29.56	31.57
156427	-	-	-	-	-	29.81	32.04
156432	-	-	-	-	-	23.04	25.36
156434	-	-	-	-	-	27.27	29.66
156435	-	-	-	-	-	29.55	31.86
156441	-	-	-	-	-	25.48	27.67
156444	-	-	-	-	-	30.99	33.22
156445	-	-	-	-	-	34.92	36.72
156446	-	-	-	-	-	27.16	29.45
156452	-	-	-	-	-	23.90	25.98
156461	-	-	-	-	-	28.27	30.94
156466	-	-	-	-	-	24.96	27.44
156469	-	-	-	-	-	27.98	30.20
156470	-	-	-	-	-	29.33	31.97
156471	-	-	37.69	-	-	32.80	34.33
156473	-	-	-	-	37.05	30.32	32.40
156489	-	-	-	-	-	28.24	30.42
156494	-	-	-	-	-	27.14	29.08

The Washington State Department of Health (DOH) Public Health Laboratories (Shoreline, WA, USA) provided us 90 patient samples. The samples were collected in March 2020 from nasopharyngeal (NP) swabs added to VTM and included 30 SARS-CoV-2 positives and 60 negatives. **Table S3** summarizes the results of the CDC singleplex test and the multiplex test for each sample.

Table S3. Ct values, SARS-CoV-2 viral load (c/μL of sample), and human RNA load (c/μL of sample) for each patient sample used in this work. Viral and RNA loads were calculated based on the Ct value from the N1 gene using the CDC singleplex test. The viral loads for the SARS-CoV-2 positive samples ranged from $1 \times 10^0 - 1 \times 10^7$ c/μL of sample with an average viral load of 6×10^5 c/μL (N=30). The detected human RNA in SARS-CoV-2 positive samples ranged from $2 \times 10^1 - 4 \times 10^3$ c/μL with an average of 8×10^2 c/μL (N=30). For the negative samples, the human RNA ranged from $1 \times 10^1 - 5 \times 10^4$ c/μL with an average of 3×10^3 c/μL. If a sample was run multiple times, the average value of the runs (either Ct or viral load) is reported. Any Ct above 40 was considered a negative result to align with MIQE guidelines(4). *These values had one or more replicate that did not result in a Ct value. ** These samples with no RP signal had very high levels of SARS-CoV-2 RNA ($>10^5$ c/μL), suggesting that the pathogen targets competitively inhibited the human target during amplification.

Patient Sample ID	SARS-CoV-2 (c/μL)	Human RNA (c/μL)	N1 Ct Singleplex	N1 Ct Multiplex	N2 Ct Singleplex	N2 Ct Multiplex	RP Ct Singleplex	RP Ct Multiplex
SARS-CoV-2 Positive Samples								
WA0361948	5.9×10^2	6.3×10^2	28.46	27.99	25.50	29.76	28.54	28.98
WA0361856	1.7×10^0	2.4×10^3	36.80	38.11*	34.61	-	26.66	26.90

WA0364405	2.7x10 ²	7.5x10 ²	29.75	29.34	27.95	32.06	28.29	28.63
WA0364834	3.1x10 ⁰	1.3x10 ²	35.93	37.16	37.80	37.51*	30.77	31.58
WA0364831	2.0x10 ⁰	2.6x10 ³	36.53	37.82	35.46	38.73*	26.57	27.14
WA0364810	2.5x10 ¹	4.3x10 ²	32.94	33.03	31.71	37.47	29.07	29.24
WA0364450	1.1x10 ²	4.5x10 ²	30.85	30.53	28.02	33.42	29.00	29.16
WA0364806	6.7x10 ³	4.1x10 ³	25.02	24.53	23.25	26.24	25.90	26.17
WA0364447	5.9x10 ³	8.9x10 ¹	25.18	24.92	22.68	26.7	31.28	35.57
WA0364449	-	2.4x10 ²	-	37.23	-	-	29.89	30.09
WA0364426	1.1x10 ¹	1.6x10 ²	34.08	34.05	32.82	38.3	30.14	30.87
WA0364428	2.8x10 ²	6.8x10 ²	29.50	29.26	26.93	31.05	28.43	28.92
WA0364416	9.6x10 ²	2.5x10 ²	27.77	27.11	24.93	28.17	29.81	30.51
WA0363478	1.1x10 ⁰	4.1x10 ²	37.42	38.10*	34.46	39.66*	29.14	29.73
WA0364750	1.1x10 ⁵	1.9x10 ²	21.08	25.41	23.51	26.99	30.21	32.39
WA0364742	1.4x10 ⁷	2.2x10 ²	14.14	25.08	24.40	26.44	30.02	31.12
WA0364746	5.4x10 ³	2.4x10 ²	25.32	37.01*	37.24	36.06*	29.91	27.36
WA0364749	1.6x10 ⁶	1.7x10 ³	19.82	20.67	21.89	21.62	27.15	**
WA0364736	2.1x10 ⁶	5.5x10 ²	16.83	13.97	14.632	14.17	28.74	**
WA0364723	1.4x10 ⁴	7.8x10 ²	23.96	27.36	25.21	29.12	28.24	28.66
WA0364727	9.5x10 ²	8.3x10 ²	27.78	16.49	15.02	16.86	28.14	**
WA0364714	5.0x10 ⁵	8.8x10 ²	18.90	18.54	18.51	19.1	28.07	**
WA0364715	6.3x10 ⁴	2.2x10 ²	21.84	27.4	27.57	29.07	30.03	36.31
WA0364718	1.1x10 ³	1.5x10 ¹	27.62	23.92	23.69	25.05	33.79	31.00
WA0364698	6.5x10 ³	1.8x10 ²	25.05	25.11	22.31	26.23	30.29	34.49
WA0364702	8.3x10 ³	1.2x10 ³	24.70	24.62	23.10	25.4	27.66	29.16
WA0364795	4.8x10 ³	1.5x10 ²	25.48	21.45	19.76	22.22	30.51	**
WA0364692	5.6x10 ²	1.8x10 ³	28.54	28.04	26.60	29.7	27.70	27.47
WA0364695	3.2x10 ³	5.3x10 ²	26.07	25.74	24.00	27.19	28.77	29.46
WA0364515	2.6x10 ⁰	1.5x10 ¹	36.20	35.61	36.87	37.37	33.80	34.04

SARS-CoV-2 Negative Samples

WA0361631	-	8.6x10 ³	-	-	-	-	27.13	30.27
WA0361632	-	3.1x10 ³	-	-	-	-	28.56	30.18
WA0361633	-	5.6x10 ³	-	-	-	33.98*	27.74	30.82
WA0361634	-	1.3x10 ⁴	-	-	-	-	26.59	29.14
WA0361635	-	1.5x10 ⁴	-	-	-	-	26.38	30.12
WA0361636	-	1.3x10 ²	-	-	-	-	33.03	30.37
WA0361637	-	9.2x10 ³	-	-	-	-	27.03	30.10
WA0361638	-	6.0x10 ³	-	-	-	-	27.64	31.18
WA0361639	-	3.7x10 ³	-	-	-	-	28.30	32.52
WA0361640	-	1.8x10 ⁴	-	-	-	-	26.11	28.68
WA0361641	-	7.0x10 ³	-	-	-	-	27.42	32.59
WA0361642	-	1.6x10 ³	-	-	-	-	29.44	30.86
WA0361643	-	3.0x10 ³	-	-	-	-	28.58	30.39
WA0361644	-	2.1x10 ³	-	-	-	-	29.09	29.47
WA0361645	-	4.4x10 ³	-	-	-	-	28.07	32.40
WA0361646	-	4.3x10 ³	-	-	-	-	28.10	33.32
WA0361647	-	9.2x10 ³	-	-	-	-	27.03	29.10
WA0361648	-	9.4x10 ³	-	-	-	-	27.01	30.69
WA0361649	-	5.4x10 ³	-	38.19*	-	-	27.79	30.11
WA0361650	-	1.4x10 ⁴	-	-	-	-	26.43	28.99
WA0361651	-	6.5x10 ³	-	-	-	-	27.51	28.96
WA0361652	-	4.4x10 ³	-	-	-	-	28.06	36.25
WA0361653	-	5.3x10 ³	-	-	-	-	27.80	33.71
WA0361654	-	1.8x10 ³	-	-	-	-	29.30	30.06
WA0361655	-	8.4x10 ²	-	-	-	-	30.38	30.69
WA0361656	-	1.1x10 ⁴	-	-	-	-	26.80	28.23

WA0361657	-	1.0x10 ³	-	-	-	-	30.13	29.38
WA0361659	-	3.8x10 ³	-	-	41.76	-	28.29	31.54
WA0361660	-	5.7x10 ³	-	-	-	-	27.70	30.81
WA0361661	-	1.3x10 ⁴	-	-	-	-	26.51	31.20
WA0634299	-	4.5x10 ²	-	-	-	-	29.01	29.39
WA0634300	-	1.1x10 ²	-	-	-	-	30.98	31.32
WA0634302	-	4.2x10 ²	-	-	-	-	29.09	29.11
WA0634303	-	7.9x10 ²	-	-	-	-	28.22	28.54
WA0634304	-	8.8x10 ¹	-	-	-	-	31.30	31.61
WA0634305	-	6.2x10 ¹	-	-	-	-	31.77	32.29
WA0634309	-	1.2x10 ³	-	-	-	-	27.67	28.48
WA0635231	-	2.2x10 ³	-	-	-	-	26.77	27.53
WA0635242	-	3.3x10 ²	-	22.00	-	22.99	29.44	38.55
WA0635243	-	3.3x10 ²	-	36.10	-	-	29.42	29.91
WA0635244	-	2.0x10 ²	-	37.73	-	-	30.13	30.87
WA0635245	-	1.0x10 ⁴	-	35.12	-	35.61*	24.62	25.35
WA0635251	-	4.3x10 ³	-	-	-	-	25.86	26.71
WA0635252	-	1.2x10 ³	-	-	-	-	27.58	28.24
WA0635397	-	1.6x10 ³	-	-	-	-	27.27	28.12
WA0635384	-	7.6x10 ²	-	-	-	-	28.28	29.00
WA0635385	-	2.0x10 ²	-	-	-	-	30.17	30.80
WA0635386	-	2.1x10 ²	-	-	-	-	30.07	31.04
WA0635387	-	1.8x10 ²	-	-	-	-	30.28	31.00
WA0634310	-	3.3x10 ²	-	-	-	-	29.43	29.65
WA0634311	-	3.8x10 ²	-	-	-	-	29.23	29.72
WA0635227	-	8.5x10 ²	-	-	-	-	28.11	28.76
WA0635228	-	4.0x10 ²	-	38.44*	-	-	29.16	29.79
WA0635229	-	1.6x10 ³	-	-	-	-	27.27	27.80
WA0635391	-	6.4x10 ²	-	-	-	-	28.52	29.35
WA0635401	-	1.5x10 ³	-	-	-	-	27.33	28.14
WA0635405	-	6.1x10 ²	-	-	-	-	28.57	29.05
WA0635410	-	1.4x10 ¹	-	-	-	-	33.86	33.96
WA0635411	-	1.1x10 ⁴	-	-	-	-	24.47	24.87
WA0635412	-	4.7x10 ⁴	-	-	-	-	22.50	22.94

Impact of viral transport media on RT-PCR. The fold-change in Ct values between the control sample of RNA in 10 mM Tris, pH 8, and RNA in VTM was calculated to determine the impact on amplification. If a condition did not have a Ct value, it was set to 45, the maximum number of cycles, to determine a ΔCt . Fold-change was calculated by first determining the ΔCt between the Tris control and the VTM experimental sample. **Figure S1** reports the ΔCt for each stock VTM/MM combination to compare to Figure 2 which reports the corresponding fold-changes in the main manuscript. Heatmaps were generated using the “*ArrayPlot*” function and the built-in “*RedGreenSplit*” color scheme in Mathematica software(2).

$$Tris\ Ct - Experimental\ Ct = \Delta Ct$$




Figure S1. The ΔC_t values used to determine the fold-change for the studies exploring the impact of VTM on the CDC singleplex test. These data correspond to the fold-change data presented in Figure 2 in the main manuscript. If a condition did not have a C_t value it was set to 45 to generate a difference in C_t measure. Conditions marked with a “✦” indicate at least one of the replicates did not have a C_t value after 45 cycles resulting in complete amplification inhibition. All reported values are averages of $N=3$ per condition. The SARS-CoV-2 and human RNA were kept constant at $820\text{ c}/\mu\text{L}$ and $2000\text{ c}/\mu\text{L}$, respectively. **A.** Impact on SARS-CoV-2 N1 target, **B.** N2 target, and **C.** the human RP target.

Fold-change was then calculated as detailed below using the ΔC_t , ‘abs’ refers to taking the absolute value of the ΔC_t . **Figure S2** shows the fold-change for conditions with varying VTM dilutions.

$$\text{Fold - change} = 2^{\text{abs}(\Delta C_t)} * \text{sign of } \Delta C_t$$

A. 1:10 VTM Dilution N1, N2, RP

	GG VTM	S2 VTM	M4RT VTM	GG VTM	S2 VTM	M4RT VTM	GG VTM	S2 VTM	M4RT VTM
TaqPath	3.2	0.8	-17337.0	1.7	-1.7	-7334.0	2.4	0.3	-20.9
Promega	4.1	0.3	-2.5	4.2	0.7	-3.9	2.5	0.4	-3.2
UltraPlex	4.9	1.4	1.2	3.8	1.3	0.6	2.9	1.1	-0.3
qScript	2.9	1.1	-1.2	3.3	1.2	-1.2	2.3	1.1	-1.3
LunaScript	3.7	1.3	-2.1	3.7	0.6	-6.6	3.1	0.4	-2.0

B. 1:100 VTM Dilution N1, N2, RP

	GG VTM	S2 VTM	M4RT VTM	GG VTM	S2 VTM	M4RT VTM	GG VTM	S2 VTM	M4RT VTM
TaqPath	0.9	1.4	-11.4	0.4	0.3	-1.3	-0.4	-0.4	-0.3
Promega	0.6	-0.2	-0.7	0.6	0.6	-1.4	-0.4	-0.4	-0.7
UltraPlex	1.4	0.5	-0.5	1.2	1.3	-1.4	0.4	0.3	-1.8
qScript	0.3	1.1	-1.5	1.2	1.2	-1.4	-1.1	1.0	-1.4
LunaScript	1.1	1.1	-0.7	-0.3	0.4	-1.1	0.3	-1.1	-1.2

C. 1:1000 VTM Dilution N1, N2, RP




Figure S2. Impact of VTM on the CDC singleplex test. The TaqPath MM was the least inhibitor tolerant while both the UltraPlex and qScript MMs were the most tolerant and even showed some amplification enhancement. The amplification enhancement and inhibition are reduced or entirely removed when diluted VTM is tested. The data presented are fold-change in Ct values between RNA spiked in VTM and control reactions of RNA spiked in 10 mM Tris buffer, pH 8. If a condition did not have a Ct value it was set to 45 to generate a difference in Ct measure. Conditions marked with a “✦” indicate at least one of the replicates did not have a Ct value after 45 cycles indicating complete amplification inhibition. All reported values are averages of N=3 per condition. The M4RT VTM resulted in the most inhibition across all dilutions and master mixes tested. **A.** Impact of 1:10 VTM dilution in 10 mM Tris, pH8, **B.** 1:100, and **C.** 1:1000.

Concordance of SARS-CoV-2 detection using the multiplex RT-PCR. SARS-CoV-2 RNA was purified from 90 patient samples and tested in the multiplex RT-PCR using the TaqPath MM. Some of these samples were tested with up to three replicates each to determine concordance. **Table S4** details the results of the replicates; a final positive v. negative determination was made based on the average of the three replicates. To identify a sample as positive, the CDC EUA requires both N1 and N2 to be detected(3). Any Ct above 40 was considered a negative result to align with MIQE guidelines(4).

Table S4. Replicates of multiplex SARS-CoV-2 RT-PCR using the TaqPath MM with purified RNA from clinical samples. Four samples were concordant across all replicates.

Patient ID	Replicate 1			Replicate 2			Replicate 3			Clinical concordance			
	Target	N1	N2	RP	N1	N2	RP	N1	N2	RP	N1	N2	RP
Positive clinical samples													
WA0361856	+	-	+	+	-	+	-	-	+	+	-	+	
WA0364834	+	-	+	+	+	+	+	-	+	+	-	+	
WA0364831	+	-	+	+	+	+	+	+	+	+	+	+	
WA0364449	+	-	+	-	-	+	No Sample			-	+		
WA0364416	+	+	+	+	+	+	+	+	+	+	+	+	
WA0363478	+	-	+	-	-	+	+	+	+	+	-	+	
WA0364746	+	-	+	-	+	+	+	+	-	+	+	+	
WA0364515	+	+	+	+	+	+	+	+	+	+	+	+	
Negative clinical samples													
WA0361633	-	+	+	-	-	+	-	-	+	-	-	+	
WA0361649	+	-	+	-	-	+	-	-	+	-	-	+	
WA0635242	+	+	+	+	+	+	+	+	+	+	+	+	
WA0635243	+	-	+	+	-	+	+	-	+	+	-	+	
WA0635244	+	-	+	-	-	+	+	-	+	+	-	+	
WA0625245	+	-	+	+	-	+	+	+	+	+	-	+	
WA0635228	+	-	+	-	-	+	-	-	+	-	-	+	
WA0365401	-	-	+	-	-	+	-	-	+	-	-	+	

References

1. CDC. CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel Product Information Sheet [Internet] SOP# CDC-006-00006 [Internet]. 2020. Available from: <https://www.fda.gov/media/134922/download>
2. Wolfram Resarch Inc. Mathematica [Internet]. Version 12. Champaign, Illinois: Wolfram Resarch Inc.; 2020. Available from: <https://www.wolfram.com/mathematica>
3. CDC. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel SOP# CDC-006-00019. 2020.
4. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines : Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin Chem. 2009;55(4):611–22.

Address for correspondence: Intellectual Ventures Laboratory, 14360 SE Eastgate Way
Bellevue, 98007, WA, USA

Samantha A. Byrnes: sbyrnes@intven.com

Ryan Gallagher: rgallagher@intven.com

John T. Connelly: jconnelly@intven.com